Apollomics Completes Patient Enrollment for Phase 3 Trial of

By Exec Edge Editorial Staff Apollomics Inc. (Nasdaq: APLM) said it completed patient enrollment in its Phase 3 bridging study for uproleselan in Chinese patients with relapsed or refractory acute myeloid leukemia. The study, conducted across 20 sites in Greater China, involved 140 adult patients and focused on evaluating the efficacy of uproleselan, an investigational […]

Related Keywords

Tianjin , China , Peking , Beijing , Chinese , Jianxiang Wang , Apollomics Inc , Union Medical College , Nasdaq , Chinese Academy Of Medical Sciences , Exec Edge Editorial , Greater China , Chinese Academy , Medical Sciences , Peking Union Medical College , Patient Enrollment , Splm ,